Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

PathSensors receives expanded license from MIT for CANARY Technology


BALTIMORE, July 9, 2020 /PRNewswire-PRWeb/ -- PathSensors Inc., a Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded the company's exclusive license to include clinical applications for CANARYtm technology. This broader license allows PathSensors to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY'stm fast and highly sensitive assays will help to address the shortage of COVID-19 testing capabilities in the United States.

The company's core business is environmental testing in fields such as building protection, mail security, food safety, and agriculture. Test panels for other infectious diseases will follow in future years.

"PathSensors originally developed CANARYtm technology for commercial use in 2012," stated PathSensors' President, Ted Olsen. "Now 8 years later, we are bringing CANARYtm to the healthcare field to provide rapid and highly sensitive detection solutions for a major public health crisis."

About CANARYtm
CANARYtm is a biosensor technology that delivers extremely rapid detection of pathogens with high sensitivity and specificity. Originally developed by scientists at MIT?Lincoln Laboratory to combat bioterrorism threats, CANARYtm has been licensed and commercialized by PathSensors, Inc.

About PathSensors, Inc.
PathSensors is a leading environmental testing company offering cutting-edge pathogen detection capabilities to a variety of industries including food safety, agriculture, infectious disease, and bioterrorism. The company makes the world a safer place by detecting pathogens that can cause sickness or worse while creating high technology jobs in the state of Maryland.

 

SOURCE PathSensors Inc.


These press releases may also interest you

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...

at 06:00
Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to...

at 06:00
...

at 06:00
The "Licensing Deals in Biotechnology 2019-2024" report has been added to  ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...



News published on and distributed by: